Evidence map›Paper›PMID 40143349›Full record

ArticleViruses2025

Prevalence of EBV, HHV6, HCMV, HAdV, SARS-CoV-2, and Autoantibodies to Type I Interferon in Sputum from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.

Ulf Hannestad, Annika Allard, Kent Nilsson, Anders Rosén

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ulf HannestadDepartment of Biomedical & Clinical Sciences, Division of Cell & Neurobiology, Linköping University, SE-58185 Linköping, Sweden.
Annika AllardDepartment of Clinical Microbiology, Clinical Virology, Umeå University, SE-90185 Umeå, Sweden.ORCID 0000-0001-6949-1213
Kent NilssonDepartment of Pain and Rehabilitation, Linköping University Hospital, SE-58758 Linköping, Sweden.
Anders RosénDepartment of Biomedical & Clinical Sciences, Division of Cell & Neurobiology, Linköping University, SE-58185 Linköping, Sweden.ORCID 0000-0001-5082-6423

Funding

Swedish Cancer Society 211832Pj01H2the Swedish Research Council 4.3-2019-00201 GD-2020-138
6 · The paper itself

Abstract

An exhausted antiviral immune response is observed in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and post-SARS-CoV-2 syndrome, also termed long COVID. In this study, potential mechanisms behind this exhaustion were investigated. First, the viral load of Epstein-Barr virus (EBV), human adenovirus (HAdV), human cytomegalovirus (HCMV), human herpesvirus 6 (HHV6), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was determined in sputum samples (n = 29) derived from ME/CFS patients (n = 13), healthy controls (n = 10), elderly healthy controls (n = 4), and immunosuppressed controls (n = 2). Secondly, autoantibodies (autoAbs) to type I interferon (IFN-I) in sputum were analyzed to possibly explain impaired viral immunity. We found that ME/CFS patients released EBV at a significantly higher level compared to controls (

Indexed as

AutoantibodiesCOVID-19Fatigue Syndrome, ChronicInterferon Type ISputumAdenoviruses, HumanAdultAgedCytomegalovirusFemaleHerpesvirus 4, HumanHerpesvirus 6, HumanHumansMaleMiddle AgedPrevalenceAutoantibodiesInterferon Type IautoAbs to interferon type IEpstein–Barr virushuman adenovirushuman cytomegalovirushuman herpesvirus 6myalgic encephalomyelitis/chronic fatigue syndrome

Identifiers

PMID40143349
PMCPMC11946815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.